DGAP-News

STADA: Executive Board gives a positive summary of 2012 at Annual General Meeting and adheres to the positive outlook till 2014 - Supervisory Board members approved

DGAP-News: STADA Arzneimittel AG / Key word(s): AGM/EGM
STADA: Executive Board gives a positive summary of 2012 at Annual
General Meeting and adheres to the positive outlook till 2014 -
Supervisory Board members approved

05.06.2013 / 16:37

---------------------------------------------------------------------

Frankfurt am Main, June 5, 2013 - At the Annual General Meeting of STADA
Arzneimittel AG, which took place today in Frankfurt am Main, Germany, the
Chairman of the Executive Board, Hartmut Retzlaff, gave a positive summary
of financial year 2012 and confirmed the Group's positive outlook until
2014. 'In 2012, we once again overcame difficult situations and at the same
time took advantage of arising opportunities thereby allowing us to
continue STADA's long-standing success story and further cement our
position in an intensifying competitive environment', said Retzlaff as
quoted from the speech's script.

Dr. Martin Abend was re-elected as Chairman of the Supervisory Board of
STADA Arzneimittel AG at the Supervisory Board meeting held directly after
the Annual General Meeting, in which the membership of all shareholder
representatives in the Supervisory Board was confirmed for another five
years. Furthermore, the Supervisory Board re-elected the employee
representative Manfred Krüger as Deputy Chairman of the Supervisory Board.

Retzlaff began his speech by discussing the developments of financial year
2012 and also commented on the events of the first quarter of 2013. The
internationalization of the STADA Group and the expansion of the branded
products were advanced as planned along with additional successes achieved
in the cost-efficiency program 'STADA - build the future'.

The Chairman of the Executive Board then summarized the Group's
opportunities and risks and confirmed the positive outlook for financial
year 2013 in view of the strategic success factors - despite the
environment which remains challenging. Retzlaff also confirmed the
long-term prognosis envisaged for 2014, which he still considers achievable
in light of an improved product and regional mix, additional cost-reduction
potential and other earnings-improving measures as well as the growth
opportunities that arise particularly in the emerging generics markets of
the market region Central Europe as well as in the market regions
CIS/Eastern Europe and Asia & Pacific.

The Annual General Meeting endorsed all of the Executive Board and
Supervisory Board's proposals. Accordingly, the Annual General Meeting